AZN Stock Recent News

ANGLE PLC (AIM:AGL, OTCQX:ANPCY), a leader in liquid biopsy technology, has signed a supplier agreement with AstraZeneca PLC (LSE:AZN) to develop an androgen receptor (AR) detection assay to enhance prostate cancer studies. An extension of a prior arrangement to develop a methodology for detecting CTC micronuclei, the latest collaboration will use ANGLE's innovative Parsortix system.

The Federal Trade Commission is challenging hundreds of alleged “junk” patent listings filed by several pharmaceutical companies, which regulators claim could increase prices for medications like Novo Nordisk's diabetes drug Ozempic by making it harder to produce generic drugs.

A dad who suffered a brain injury just days after receiving a British-developed COVID vaccine has told Sky News he would never have had the jab if he had known of the risk of rare but serious side effects.

AstraZeneca PLC (LSE:AZN) has admitted in court that its Covid-19 vaccines can cause rare side effects. A legal document submitted to London's High Court in February said the vaccine, developed alongside Oxford University, “can, in very rare cases, cause TTS”.

Since I covered AstraZeneca last October, shares have narrowly outperformed the S&P 500 index. Thanks to impressive results throughout the business, the company's total revenue and core EPS jumped in the first quarter. AstraZeneca's interest coverage ratio remains robust, and the dividend remains amply covered with free cash flow.

Markets Defused aims to present an easy-to-understand and straightforward recap of the week's most engaging stock market news BHP takeover approach spurned by Anglo American Meta shareholders have an AI problem Alphabet revenues soared as it hailed the ‘Gemini era' Microsoft revealed another big boost from AI Microsoft-backed Rubrik soared in New York debut Peacock in the spotlight but Comcast stock dipped BHP takeover approach spurned by Anglo American Australian mining major BHP Billiton had its takeover advances spurned by Anglo American. BHP on Thursday launched a £31.1 billion proposal to buy up the assets of is smaller international mining rival in an ‘all-paper' transaction –offering new BHP shares to Anglo shareholders whilst also proposing to split off Anglo's platinum business to allay monopoly fears.

Barclays has raised its price target for shares in AstraZeneca PLC (LSE:AZN) after Thursday's significantly better-than-expected first-quarter numbers. The investment banking arm of the high street lender reckons the stock is worth £135, a 12% premium to the current price.

AstraZeneca (AZN) beats first-quarter estimates for earnings and sales, driven by increased demand for its key oncology and rare disease drugs.

Pascal Soriot, CEO of AstraZeneca, joins the Bloomberg Intelligence to discuss AstraZeneca earnings, along with regulatory and scientific updates. He spoke with Paul Sweeney and Molly Smith on Bloomberg Radio.

AstraZeneca shares (AZN) revealed a first-quarter earnings beat on Thursday, posting revenue of $12.68 billion, a 19% year-over-year gain. In addition, the pharmaceutical giant has reiterated its full-year guidance by claiming its "core EPS is expected to increase by a low double-digit to low teens percentage.